Great Point Partners LLC Tricida, Inc. Transaction History

Great Point Partners LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$8.51 - $13.6 $2.51 Million - $4.01 Million	-294,763 Reduced 25.31%	870,000 $9.12 Million
Q2 2022 Aug 15, 2022	SELL	$7.31 - $11.85 $623,082 - $1.01 Million	-85,237 Reduced 6.82%	1,164,763 $11.3 Million
Q1 2022 May 16, 2022	SELL	$7.35 - $10.63 $1.1 Million - $1.59 Million	-150,000 Reduced 10.71%	1,250,000 $10.3 Million
Q4 2021 Feb 14, 2022	SELL	$4.19 - $9.56 $2.41 Million - $5.49 Million	-574,000 Reduced 29.08%	1,400,000 $13.4 Million
Q2 2021 Aug 16, 2021	BUY	$3.95 - $5.41 $6.42 Million - $8.79 Million	1,624,400 Added 464.65%	1,974,000 $8.53 Million
Q1 2021 May 17, 2021	BUY	$4.52 - $7.8 $1.58 Million - $2.73 Million	349,600 New	349,600 $1.85 Million
Q4 2019 Feb 14, 2020	SELL	$29.6 - $43.71 $17.4 Million - $25.7 Million	-586,929 Closed	0 $0
Q3 2019 Nov 15, 2019	SELL	$29.87 - $42.22 $25 Million - $35.3 Million	-837,069 Reduced 58.78%	586,929 $18.1 Million
Q2 2019 Aug 14, 2019	BUY	$31.16 - $39.46 $44.4 Million - $56.2 Million	1,423,998 New	1,423,998 $0

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Great Point Partners LLC with notifications on news.